Business & Finance
OptiBiotix secures license agreement with Tata Chemicals for Indian market
23 October 2023 -

Life sciences busines OptiBiotix Health plc (AIM: OPTI) revealed on Monday that it has entered into a licence agreement with science company Tata Chemicals Limited to integrate Tata's proprietary Fossence into OptiBiotix's SlimBiome and LeanBiome products for the Indian market.

Fossence, a short-chain fructo-oligosaccharide (FOS), replaces the FOS used in SlimBiome in other markets. The agreement includes the approval for the use of the Fossence logo on products containing SlimBiome in India.

Tata Chemicals operates in industrial chemicals, food and nutrition (Tata NQ), and agriculture. It is part of the Tata Group with annual revenues of USD300bn in 2022.

OptiBiotix Health, formed in March 2012, focuses on developing compounds to modify the human microbiome for disease prevention, management and wellness. The company collaborates with leading academics in its extensive R&D program and has signed agreements with over twenty international food and healthcare supplement companies. OptiBiotix is also developing its own range of consumer supplements, with current areas of focus including obesity, cardiovascular health and diabetes.